Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

Dow Jones

Feb 05, 2025

0838 GMT - Novo Nordisk's initial 2025 outlook is just ahead of Jefferies's expectations. But given a higher starting point and stronger currency effects it suggests up to 6% sales and 10% EBIT consensus upgrades, analysts at the bank write. Novo Nordisk's fourth-quarter sales beat expectations by 5%, mostly on positive U.S. gross-to-net adjustments--the discount offered between the list price and the actual net sales price--for its insulins. Sales of Wegovy were shy of expectations while Ozempic and Rybelsus were in line. A better gross margin, higher research and development costs but less selling and distribution spend helped EBIT beat by 9% and EPS by 6%. The stock will likely tick higher initially but could then fade, Jefferies says. Shares trade 4.2% higher at 617.20 Danish kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

February 05, 2025 03:38 ET (08:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2509471648"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509471648\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509471648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-05 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509471648","market":"us","top_or_hot":-1,"title":"Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0838 GMT - Novo Nordisk's initial 2025 outlook is just ahead of Jefferies's expectations. But given a higher starting point and stronger currency effects it suggests up to 6% sales and 10% EBIT consensus upgrades, analysts at the bank write. Novo Nordisk's fourth-quarter sales beat expectations by 5%, mostly on positive U.S. gross-to-net adjustments--the discount offered between the list price and the actual net sales price--for its insulins. Sales of Wegovy were shy of expectations while Ozempic and Rybelsus were in line. A better gross margin, higher research and development costs but less selling and distribution spend helped EBIT beat by 9% and EPS by 6%. The stock will likely tick higher initially but could then fade, Jefferies says. Shares trade 4.2% higher at 617.20 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 03:38 ET (08:38 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-05 16:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0838 GMT - Novo Nordisk's initial 2025 outlook is just ahead of Jefferies's expectations. But given a higher starting point and stronger currency effects it suggests up to 6% sales and 10% EBIT consensus upgrades, analysts at the bank write. Novo Nordisk's fourth-quarter sales beat expectations by 5%, mostly on positive U.S. gross-to-net adjustments--the discount offered between the list price and the actual net sales price--for its insulins. Sales of Wegovy were shy of expectations while Ozempic and Rybelsus were in line. A better gross margin, higher research and development costs but less selling and distribution spend helped EBIT beat by 9% and EPS by 6%. The stock will likely tick higher initially but could then fade, Jefferies says. Shares trade 4.2% higher at 617.20 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 05, 2025 03:38 ET (08:38 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2509471648","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509471648","pubTimestamp":1738744680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0838 GMT - Novo Nordisk's initial 2025 outlook is just ahead of Jefferies's expectations. But given a higher starting point and stronger currency effects it suggests up to 6% sales and 10% EBIT consensus upgrades, analysts at the bank write. Novo Nordisk's fourth-quarter sales beat expectations by 5%, mostly on positive U.S. gross-to-net adjustments--the discount offered between the list price and the actual net sales price--for its insulins. Sales of Wegovy were shy of expectations while Ozempic and Rybelsus were in line. A better gross margin, higher research and development costs but less selling and distribution spend helped EBIT beat by 9% and EPS by 6%. The stock will likely tick higher initially but could then fade, Jefferies says. Shares trade 4.2% higher at 617.20 Danish kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德盈利和指引意味着共识升级——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0838 GMT - Novo Nordisk's initial 2025 outlook is just ahead of Jefferies's expectations. But given a higher starting point and stronger currency effects it suggests up to 6% sales and 10% EBIT consensus upgrades, analysts at the bank write. Novo Nordisk's fourth-quarter sales beat expectations by 5%, mostly on positive U.S. gross-to-net adjustments--the discount offered between the list price and the actual net sales price--for its insulins. Sales of Wegovy were shy of expectations while Ozempic and Rybelsus were in line. A better gross margin, higher research and development costs but less selling and distribution spend helped EBIT beat by 9% and EPS by 6%. The stock will likely tick higher initially but could then fade, Jefferies says. Shares trade 4.2% higher at 617.20 Danish kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 05, 2025 03:38 ET (08:38 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}